Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer’s disease

Author(s): Sung, YJ; Yang, C; Norton, J; Johnson, M; Fagan, A; Bateman, RJ; Perrin, RJ; Morris, JC; Farlow, MR; Chhatwal, JP; Schofield, PR; Chui, H; Wang, F; Novotny, B; Eteleeb, A; Karch, C; Schindler, SE; Rhinn, H; Johnson, ECB; Oh, HS; Rutledge, JE; Dammer, EB; Seyfried, NT; Wyss-Coray, T; Harari, O; Cruchaga, C;
Year: 2023;  
Journal: Science Translational Medicine;  
Volume: 15;  
Issue: 703;  

Proteomic studies for Alzheimer’s disease (AD) are instrumental in identifying AD pathways but often focus on single tissues and sporadic AD cases. Here, we present a proteomic study analyzing 1305 proteins in brain tissue, cerebrospinal fluid (CSF), and plasma from patients with sporadic AD, TREM2 risk variant carriers, patients with autosomal dominant AD (ADAD), and healthy individuals. We identified 8 brain, 40 CSF, and 9 plasma proteins that were altered in individuals with sporadic AD, and we replicated these findings in several external datasets. We identified a proteomic signature that differentiated TREM2 variant carriers from both individuals with sporadic AD and healthy individuals. The proteins associated with sporadic AD were also altered in patients with ADAD, but with a greater effect size. Brain-derived proteins associated with ADAD were also replicated in additional CSF samples. Enrichment analyses highlighted several pathways, including those implicated in AD (calcineurin and Apo E), Parkinson’s disease (α-synuclein and LRRK2), and innate immune responses (SHC1, ERK-1, and SPP1). Our findings suggest that combined proteomics across brain tissue, CSF, and plasma can be used to identify markers for sporadic and genetically defined AD.